THC heads into its July 24 earnings report with the Street broadly constructive but watching one specific risk that could reframe the full-year story.
Analyst activity in the run-up has been mostly target trimming with ratings held firm. Guggenheim cut its target to $242 from $252 on Monday while keeping its Buy. Wells Fargo moved the other way last week, lifting to $231 from $213 on an Overweight. Barclays nudged its target to $240 earlier in the month, also Overweight. The consensus mean target of $244 sits roughly 25% above the current price of $194, a wide gap that reflects how far the stock still trails the Street's base case rather than any sudden burst of optimism.
The bull-bear divide is sharp. Bears point to the expiration of ACA subsidies, which could strip coverage from 80-85% of THC's subsidy-dependent patient population. The Acute Care segment faces an estimated $220 million headwind, with a further $30 million in USPI, and a one-time $148 million Medicaid boost in the prior period makes the comparison even harder. Bulls counter with the USPI ambulatory surgery platform — higher margins, faster growth, and expanding equity earnings projections for 2026 — arguing that mix shift toward outpatient revenue reduces the company's dependence on the patients most exposed to policy risk. The PE multiple of roughly 11x and EV/EBITDA near 7x keep valuation in the supportive zone for that bull case. THC's EPS surprise factor score ranks in the 90th percentile, meaning the company has consistently beaten expectations even when the setup looked challenging.
The short side tells a relaxed story heading in. Short interest has eased about 2% over the past week to 4.4% of the float — not high enough to create squeeze dynamics, and the borrow market is exceptionally loose, with availability running above 3,300%, meaning shares are freely available to anyone wanting to build a new short position. Cost to borrow has dropped 26% over the past week to just 0.34%, a multi-month low. The put/call ratio of 1.34 is actually slightly below its 20-day average of 1.40, suggesting options traders have not rushed to add downside protection. The stock has gained 13% over the past month despite barely moving this week, and nearest peer HCA fell 5% on the week versus THC's flat performance — a relative resilience worth noting. The ORTEX short score of 37 is mid-range and stable, consistent with a stock where bears are present but not pressing aggressively.
Thursday's print is therefore less a test of whether USPI is growing and more a test of how management quantifies the subsidy expiration impact and whether the underlying volume and payer mix trends in Acute Care are strong enough to absorb it.
See the live data behind this article on ORTEX.
Open THC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
